A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA).

Florence Laigle-DonadeyFrançois DucrayMatthieu BooneMamadou Hassimiou DialloDavid HajageCarole RamirezOlivier ChinotDamien RicardJean-Yves Delattre

Published in: Neuro-oncology advances (2019)

Dexamphetamine at a dosage of up to 30 mg/day for 3 months has acceptable tolerability in PBT patients but does not improve fatigue, cognitive function, or QOL.

Keyphrases

phase iii
placebo controlled
double blind
end stage renal disease
clinical trial
open label
ejection fraction
chronic kidney disease
phase ii
newly diagnosed
prognostic factors
peritoneal dialysis
computed tomography
magnetic resonance
bone mineral density
patient reported
dual energy